Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Ann Intern Med. 2020 Sep 15;173(6):505-506. doi: 10.7326/L20-0054.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / complications
  • Antiphospholipid Syndrome* / drug therapy
  • Factor Xa Inhibitors / therapeutic use
  • Humans
  • Rivaroxaban* / therapeutic use
  • Vitamin K

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Vitamin K
  • Rivaroxaban